← All trials
NCT00526643
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2007
- Primary completion
- Dec 1, 2012
- Completion date
- Dec 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 57
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Fondazione Giovanni PascaleLead sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteOverall official - principal investigator
- Gruppo Oncologico Italia MeridionaleOverall official - principal investigator
- Gruppo Oncologico Italiano di Ricerca ClinicaOverall official - principal investigator
- Gruppo Oncologico del Nord-OvestOverall official - principal investigator
- Fondazione Giovanni PascaleOverall official - principal investigator
- University of Campania Luigi VanvitelliOverall official - principal investigator
- Federation of Italian Cooperative Oncology GroupsOverall official - principal investigator
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteCollaborator
- Gruppo Oncologico Italia MeridionaleCollaborator
- Northwest Oncology Cooperative GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.